Plain-English translation of NCT06821100 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a medication called thymalfasin (also known as Ta1), which is designed to boost your immune system's ability to fight infections. Researchers want to see if giving this medication before a COVID-19 booster vaccine can help your body build a stronger immune response to the vaccine. The study will test different doses of the medication to understand how safe it is and whether it actually improves vaccine effectiveness in older adults.
As we age, our immune systems naturally become weaker, which means COVID-19 vaccines may not work as well for older adults. This trial exists to explore whether this medication could help strengthen the immune response to vaccination, potentially offering better protection against COVID-19 in seniors.
You likely qualify if…
You likely don't qualify if…
You would receive injections of the study medication (or placebo) on one or two separate days before getting your COVID-19 booster vaccine. Your healthcare team will monitor you for safety and collect blood samples to measure how well your immune system responds to the vaccine. The study is designed as a Phase 1 trial, meaning researchers are primarily focused on understanding safety and finding the right dose, rather than proving the medication works.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
United States